Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system.
about
Hepatic artery adjuvant chemotherapy for patients having resection or ablation of colorectal cancer metastatic to the liverHepatic artery adjuvant chemotherapy for patients having resection or ablation of colorectal cancer metastatic to the liverSurgical resection of hepatic metastases from colorectal cancer: a systematic review of published studiesPreoperative selection of patients with colorectal cancer liver metastasis for hepatic resectionAdjuvant chemotherapy for resected colorectal cancer metastases: Literature review and meta-analysisSurgery for colorectal liver metastases: The evolution of determining prognosisFIRST BRAZILIAN CONSENSUS ON MULTIMODAL TREATMENT OF COLORECTAL LIVER METASTASES. MODULE 1: PRE-TREATMENT EVALUATIONRecent Advances in Chemotherapy and Surgery for Colorectal Liver MetastasesPreoperative galactose elimination capacity predicts complications and survival after hepatic resectionDecision analysis for the cost-effective management of recurrent colorectal cancerStatus of hyperthermia in the treatment of advanced liver cancer.Long-term outcome after sequential resections of liver and lung metastases from colorectal carcinoma.Defining patient outcomes in stage IV colorectal cancer: a prospective study with baseline stratification according to disease resectability statusInteraction of tumour biology and tumour burden in determining outcome after hepatic resection for colorectal metastases.Maximum Diameter and Number of Tumors as a New Prognostic Indicator of Colorectal Liver MetastasesPathological response grade of colorectal liver metastases treated with neoadjuvant chemotherapyIs the clinical risk score for patients with colorectal liver metastases still useable in the era of effective neoadjuvant chemotherapy?Identification of prognostic inflammatory factors in colorectal liver metastases.Surgery for colorectal liver metastases with hepatic lymph node involvement: a systematic review.Outcome of microscopic incomplete resection (R1) of colorectal liver metastases in the era of neoadjuvant chemotherapy.A nomogram predicting disease-free survival in patients with colorectal liver metastases treated with hepatic resection: multicenter data collection as a Project Study for Hepatic Surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery.Colorectal cancer with liver metastases: neoadjuvant chemotherapy, surgical resection first or palliation alone?Exploring gene expression signatures for predicting disease free survival after resection of colorectal cancer liver metastasesRescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival.Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors.Colorectal hepatic metastasis: Evolving therapies.Complications following liver resection for colorectal metastases do not impact on longterm outcomeCombining partial liver resection and local ablation of liver tumours: a preliminary Dutch experience.RAS mutations predict radiologic and pathologic response in patients treated with chemotherapy before resection of colorectal liver metastases.Gene expression profiles accurately predict outcome following liver resection in patients with metastatic colorectal cancer.Neo-adjuvant chemotherapy followed by surgery versus surgery alone in high-risk patients with resectable colorectal liver metastases: the CHARISMA randomized multicenter clinical trial.Novel methods for clinical risk stratification in patients with colorectal liver metastasesColorectal liver metastasesMeta-analysis of KRAS mutations and survival after resection of colorectal liver metastases.Positive postoperative CEA is a strong predictor of recurrence for patients after resection for colorectal liver metastases.The role of neoadjuvant chemotherapy for resectable colorectal liver metastases: a systematic review and meta-analysis.Assessing the management of hepatic colorectal cancer metastases: is treatment consistent in Ontario?Metastatic Tissue Proteomic Profiling Predicts 5-Year Outcomes in Patients with Colorectal Liver Metastases.Neoadjuvant and conversion treatment of patients with colorectal liver metastasis: the potential role of bevacizumab and other antiangiogenic agentsLymphatic Invasion is an Independent Adverse Prognostic Factor in Patients with Colorectal Liver Metastasis.
P2860
Q24244065-52B97115-5B75-4E1B-9454-FC59B376062FQ24247230-9F279AC0-2E20-430C-A9DD-62BBB956D1FBQ24651894-9728D391-8A2F-4B02-AC81-3F52BA35C176Q26774687-4D8E2BC7-D438-4B07-B290-BFADE3D3CCDCQ26774704-C4609583-7ED6-42A9-B18A-17FB6051DA0DQ27694490-36060EB0-C793-412E-8632-25ECCF758B71Q28066171-AB827E21-424F-4253-B394-83A3350B5A19Q28067408-56E88C22-1066-45BA-B72C-36782BCD28CEQ28344083-810A9EC1-2578-4E02-B06B-5915EB774606Q28354061-70A435BC-478C-4527-B196-62577830A2DBQ30704873-35A7C40B-14E0-4F31-A567-F23E503618E1Q33563648-35F506F7-0B08-49DD-99AF-8CBEEFE3B636Q33630882-6442AF89-3B8D-4D08-B4B8-F204AB739A3EQ33679628-DEF9E231-B29E-492F-964D-B2E337355423Q33770802-470F4EF7-BC5F-4109-A582-2A407D248A2BQ33865047-E359CB01-6AD3-4057-AA90-7452157A352AQ33921511-0EECC6CA-A8EB-47B0-B665-2C76C1B49C21Q34017917-96BD592E-BF6C-444A-B7BE-BE550A718C8AQ34022493-BBADDBD3-CEBF-4E60-A217-189C094659A9Q34050151-A05DC1EE-5D09-44D5-9DAB-45968D441818Q34054823-B650B49A-CAF7-410B-98EE-47C8C33A2D3CQ34207776-A54EDE5C-BD48-4807-A1F8-2AFBD0A5121CQ34490042-09489BCA-AE36-475D-8375-BC096C93B66DQ34551117-2C5A02A8-740A-4E37-9F1C-9D090B755D7CQ34645408-3CA850BC-55EB-440E-A881-927525C15DC1Q34663557-49ACB1FA-3ACB-43BD-BC00-D7B52097F8A6Q34986203-22AA2C3A-7EDD-496C-8F69-2DACC4265D35Q35005564-AD6AB179-9F1C-4845-B5C7-8B0CCB3CA80DQ35054390-D7149474-C2BC-4416-999C-33DE9014414AQ35067591-B61404E3-CAB1-44B0-AA2F-061286B18FACQ35225671-55ACF6FE-5233-46C0-A613-DD34FA66C131Q35429661-3A29737A-C52F-447D-8173-52C4DEBB47F6Q35687594-3626D426-9800-4B30-8A0A-D3CCEC699FC8Q35709696-D4B49540-9256-4668-A885-644C78CB89A3Q35921079-F8C9DC13-8F75-43F5-BD2C-39069ECEE398Q35988684-833B4F7B-FE83-4E29-A93A-3AFB464DEF38Q36063326-75EB8635-CB3B-4C1C-815B-0DC715304443Q36165524-8D1A7F6B-8969-4D70-B764-C3A6341BF083Q36343047-0C91BC3B-901A-4CAB-97C7-47256AA082EBQ36391787-061BC425-699B-426A-814A-2D73042DCC43
P2860
Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system.
description
1999 nî lūn-bûn
@nan
1999 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Hepatic resection for metastat ...... f a prognostic scoring system.
@ast
Hepatic resection for metastat ...... f a prognostic scoring system.
@en
Hepatic resection for metastat ...... f a prognostic scoring system.
@nl
type
label
Hepatic resection for metastat ...... f a prognostic scoring system.
@ast
Hepatic resection for metastat ...... f a prognostic scoring system.
@en
Hepatic resection for metastat ...... f a prognostic scoring system.
@nl
prefLabel
Hepatic resection for metastat ...... f a prognostic scoring system.
@ast
Hepatic resection for metastat ...... f a prognostic scoring system.
@en
Hepatic resection for metastat ...... f a prognostic scoring system.
@nl
P2093
P2860
P1476
Hepatic resection for metastat ...... f a prognostic scoring system.
@en
P2093
A C Bonham
D A Geller
I Dvorchik
J R Madariaga
S Iwatsuki
T J Gayowski
P2860
P304
P356
10.1016/S1072-7515(99)00089-7
P577
1999-09-01T00:00:00Z